Citation Impact
Citing Papers
Regulation of Kiss1 Gene Expression in the Brain of the Female Mouse
2005 Standout
Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
2014
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Pharmacotherapy of type 2 diabetes: An update
2017
Excitatory Amino Acid Receptors and Puberty
1998
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Symptoms of hypoglycaemia in people with diabetes
2001
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2014
Phosphorylated and nonphosphorylated prolactin isoforms
1994
Cholinergic control of growth hormone (GH) responses to GH‐releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback
1993
The adolescent brain and age-related behavioral manifestations
2000 Standout
Neuromodulation in Polycystic Ovary Syndrome
2001
Glutamate decarboxylase autoimmunity and growth hormone secretion in type I diabetes mellitus
1997
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
2016
Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
2014
Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
2015
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
2014
Acromegaly: An Endocrine Society Clinical Practice Guideline
2014 Standout
Diagnosis and Complications of Cushing’s Syndrome: A Consensus Statement
2003 Standout
Canagliflozin
2014
Type 2 diabetes
2017 Standout
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
2014
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
2016
The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
2014
Differential effects of the N-methyl-d-aspartate and non-N-methyl-d-aspartate receptors of the excitatory amino acids system on LH and FSH secretion. Its effects on the hypothalamic luteinizing hormone releasing hormone during maturation in male rats
1996
Insulin in the Brain: Its Pathophysiological Implications for States Related with Central Insulin Resistance, Type 2 Diabetes and Alzheimer’s Disease
2014
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
2015
How (and why) the immune system makes us sleep
2009
Duration and severity of hypoglycemia needed to induce neuropathy
1990
Type 2 diabetes mellitus
2015 Standout
Polycystic ovary syndrome
2016 Standout
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2015
Growth hormone neuroregulation in diabetes mellitus
1994
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
The Role of Cytokines in the Regulation of Neurotransmission
2008
Neuroinflammation: the devil is in the details
2016 Standout
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human*
1998 Standout
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
2014
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
2014
Neurobiological Mechanisms of the Onset of Puberty in Primates*
2001
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
The Effects of Animals on Human Health and Well‐Being
2009 Standout
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
The influence of absorption enhancers on intranasal insulin absorption in normal and diabetic subjects
1996
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Cyclodextrin Drug Carrier Systems
1998 Standout
Excitatory Amino Acids: Evidence for a Role in the Control of Reproduction and Anterior Pituitary Hormone Secretion*
1997
Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysis
2013
Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis
2018
Novel Agents for the Treatment of Type 2 Diabetes
2014
Diabetic Kidney Disease
2017 Standout
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
2015
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
2016
Thyroid Hormone Regulation of Metabolism
2014 Standout
Efficacy and safety of dual add‐on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52‐week, randomized, active‐controlled trial
2020
How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions*
2000 Standout
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
2014
The Timing of Normal Puberty and the Age Limits of Sexual Precocity: Variations around the World, Secular Trends, and Changes after Migration
2003 Standout
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
2014
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials
2016
Diabetic Autonomic Neuropathy
2003 Standout
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
2013 Standout
Multimodal Influence of Estrogen upon Gonadotropin-Releasing Hormone Neurons
1998
Defective Glucose Counterregulation after Strict Glycemic Control of Insulin-Dependent Diabetes Mellitus
1987
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus
2016
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
The Relevance of Glucose Counterregulatory Systems to Patients with Insulin-Dependent Diabetes Mellitus*
1986
Works of Pablo Arias being referenced
Interleukin-1 Inhibits NMDA-Stimulated GnRH Secretion: Associated Effects on the Release of Hypothalamic Inhibitory Amino Acid Neurotransmitters
1999
Ontogenic changes in the hypothalamic levels of amino acid neurotransmitters in the female rat
1994
Involvement of gamma amino butyric acid (GABA) in the postnatal function of the GnRH pulse generator as determined on the basis of GnRH and GnRH-receptor gene expression in the hypothalamus and the pituitary
2009
Sexual Maturation Modifies the Catecholaminergic Control of Gonadotrophin Secretion and the Effect of Ovarian Hormones on Hypothalamic Neurotransmitters in Female Rats
1990
Preoptic Release of Amino Acid Neurotransmitters Evaluated in Peripubertal and Young Adult Female Rats by Push-Pull Perfusion
1993
Effect of Insulin on LHRH Release by Perifused Hypothalamic Fragments
1992
Intranasal Insulin Administration in Insulin Dependent Diabetes:
1990
Estradiol Modulates the LH Release Response to N-Methyl-<i>D</i>-Aspartate in Adult Female Rats: Studies on Hypothalamic Luteinizing Hormone-Releasing Hormone and Neurotransmitter Release
1993
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
2013
Lipoprotein Alterations, Hepatic Lipase Activity, and Insulin Sensitivity in Subclinical Hypothyroidism: Response to L-T 4 Treatment
2007
Abnormal growth hormone levels in insulin-dependent diabetic patients under continuous subcutaneous insulin infusion and intensified conventional treatment
1984
Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
2014
Incidence of Hypoglycemic Episodes in Diabetic Patients Under Continuous Subcutaneous Insulin Infusion and Intensified Conventional Insulin Treatment: Assessment by Means of Semiambulatory 24-hour Continuous Blood Glucose Monitoring
1985